Free Trial
NASDAQ:IMNM

Immunome Q4 2024 Earnings Report

Immunome logo
$8.63 +0.03 (+0.35%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$8.65 +0.02 (+0.23%)
As of 04:22 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunome EPS Results

Actual EPS
-$0.84
Consensus EPS
-$0.68
Beat/Miss
Missed by -$0.16
One Year Ago EPS
N/A

Immunome Revenue Results

Actual Revenue
$2.74 million
Expected Revenue
$3.07 million
Beat/Miss
Missed by -$330.00 thousand
YoY Revenue Growth
N/A

Immunome Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Wednesday, March 19, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Immunome's Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled on Wednesday, August 6, 2025 at 12:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Immunome Earnings Headlines

Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
Immunome initiated with a Buy at Lake Street
See More Immunome Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immunome? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunome and other key companies, straight to your email.

About Immunome

Immunome (NASDAQ:IMNM), a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

View Immunome Profile

More Earnings Resources from MarketBeat